用于固体瘤治疗的CDK9抑制剂
Christiana Mo1, Ning Wei2, Terence Li2
1Department of Oncology, Montefiore Einstein, Bronx, NY, USA; Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA.
循环素依赖性激酶9 (CDK9) 是转录的关键调节剂,在许多癌症中过度表达. 这篇评论探讨了CDK9的研究.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环素依赖性激酶9 (CDK9) 在通过RNA聚合酶II (Pol II) 延长来调节mRNA转录中起着至关重要的作用.
- 过度表达CDK9与癌症的发展和较差的临床结果有关,这使其成为癌症的重要驱动因素.
- 虽然CDK9抑制在血液癌症中得到了广泛的研究,但其在固体瘤中的作用正在引起人们的注意.
研究的目的:
- 在固体瘤的背景下,审查目前对CDK9生物学的理解.
- 总结小分子CDK9抑制剂的开发和研究.
- 讨论最近的临床试验结果和提高CDK9抑制剂在固体瘤中的疗效的策略.
主要方法:
- 科学出版物和临床试验数据的文献综述.
- 分析CDK9在固体瘤中的瘤信号通路中的作用.
- 评估小分子CDK9抑制剂及其临床性能.
主要成果:
- CDK9的过度表达在各种固体瘤中普遍存在,驱动瘤性途径.
- 小分子CDK9抑制剂显示出希望,但在临床应用中面临挑战.
- 最近的临床试验提供了关于CDK9抑制剂的疗效和局限性的见解.
结论:
- CDK9是固体瘤的可行的治疗标,目前正在研究优化抑制剂策略.
- 需要进一步研究以克服抗药性机制并改善CDK9抑制剂患者的治疗结果.
- 提高CDK9抑制剂的治疗效果需要针对特定的固体瘤环境和组合疗法的专注方法.
更多相关视频
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Positive Regulator Molecules
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
